ROCKET PHARMACEUTICALS, INC.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Goodwill
Goodwill is tested for impairment annually as of December 31, or more frequently when events or changes in circumstances indicate that the asset might be impaired.
On May 27, 2025, the Company announced that a patient participating in the Phase 2 clinical trial for RP-A501 for Danon disease experienced an SAE and that the FDA placed a clinical hold on the trial to allow for further evaluation. In response to the SAE, the Company performed a quantitative assessment of its goodwill and determined that it is more likely than not that the fair value of the Company exceeds the carrying value. As a result, the Company has determined that there wasno goodwill impairment as of and for the quarter ended June 30, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.